Alzheimer’s disease, frontotemporal dementias, progressive supranuclear palsy, Corticobasal degeneration, Clinical Trial Study
< Back to Find a Trial

Phase 3b Open-Label, Multicenter, Safety Study of BIIB037 (Aducanumab) in Subjects With Alzheimer's Disease Who Had Previously Participated in the Aducanumab Studies 221AD103, 221AD301, 221AD302 and 221AD205 (Biogen221AD304)

ID
NCT04241068
Condition Studied
Alzheimer's Disease
Phase
Phase III
Status
Active, but no longer recruiting
Intervention
Aducanumab
Principal Investigator
Sponsor
Biogen

Please go to ClinicalTrials.gov for more information.